Raleigh, North Carolina

Velocity Clinical Research at Raleigh Neurology

Velocity’s Neurology research site in Raleigh partners with Raleigh Neurology Associates, P.A., to conduct clinical trials related to disorders of the nervous system. Raleigh Neurology began conducting clinical trials in 1996 and later partnered with Meridian Clinical Research before being acquired by Velocity in 2022.

Through the partnership with Raleigh Neurology, the site is easily accessible to thousands of patients in the Research Triangle, including those established with the practice. All trials conducted at the site are performed in accordance with ICH and FDA guidelines, and in compliance with GCP. Our Raleigh team is committed to being a resource for study participants, to providing the highest quality of patient care with compassion and kindness, and to advancing medicine through research.

Velocity Clinical Research at Raleigh Neurology
1520 Sunday Drive, Suite 315, Raleigh, NC 27607

Phone: (984) 251-1336

Email: info@velocityclinical.com

Find a Clinical Trial in Raleigh
Use the dropdown to browse current studies in Raleigh.

Follow Velocity on Facebook for company updates and more.

Portrait Of Medical Team Standing Outside Hospital

About Velocity Clinical Research

155,000+ people have a joined a study at Velocity

Many people enjoy the study experience and have joined several clinical trials at Velocity.

Velocity has decades of research experience

With sites that were established as long ago as 1986, Velocity has experts who have supported clinical trials for decades.

Velocity studies are led by healthcare professionals

All clinical trials conducted at Velocity are overseen by the U.S. Food and Drug Administration (FDA).

Our experienced research team in Raleigh

Every clinical trial is overseen by a Principal Investigator – a physician who is responsible for the rights, safety and welfare of the study participants. All physicians at Velocity are board certified in their specialty area(s) and all research staff is trained in clinical research regulations, including GCP and HIPAA. Our clinical research team in Raleigh is dedicated to conducting quality research in a professional and caring environment.

  • Kenneth Carnes, MD, PhD

    Principal Investigator
    Board certified in neurology, Kenneth Carnes, MD, PhD received his undergraduate degree in neurobiology from Brown University, and earned a combined MD/PhD from Washington University in St. Louis. Dr. Carnes completed a residency in adult neurology at Washington University Medical Center and a fellowship in Stroke Rehabilitation and Electrodiagnostic Studies at Washington University. He also completed an internship in internal medicine at Barnes-Jewish Hospital in St. Louis.

  • Casey F. Jeffreys, MD

    Principal Investigator
    Board certified in neurology, Casey F. Jeffreys, MD received her Bachelor of Science in neural science at New York University and her MD from the University of North Carolina School of Medicine. Dr. Jeffreys completed an internal medicine internship, neurology residency, and fellowship training in multiple sclerosis and neuroimmunology at Duke University. Additionally, she completed a residency in neurology and a fellowship in epilepsy and sleep medicine at Duke University Medical Center.

  • Thomas Perkins, MD, PhD

    Principal Investigator
    Board certified in neurology and in Sleep Medicine through the American Boards of Sleep Medicine and of Psychiatry and Neurology, Thomas Perkins, MD, PhD has a subspecialty in sleep medicine. Dr. Perkins joined Raleigh Neurology in 1997, where he developed and now directs the Sleep Medicine Program, which has the distinction of being nationally accredited since 2002. He is actively involved in the clinical research of sleep disorders and epilepsy and enjoys opportunities to lecture on sleep-related topics, as well as publishing his research. He received his BS in biology in 1985 from Muskingum College in New Concord, Ohio, his MD from the Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM), and earned a PhD in neurobiology at NEOUCOM, in conjunction with Kent State University, studying the electrophysiologic and pharmacologic mechanisms of learning and memory. Dr. Perkins also completed an internship at Akron City Hospital.

  • Bradley Robottom, MD

    Principal Investigator
    Bradley Robottom, MD practices general neurology with special interests in clinical research and in the use of botulinum toxin (Botox®) for neurological disorders. Dr. Robottom earned an MD from the Medical University of South Carolina. Since then, he served on the faculty at the University Of Maryland School Of Medicine, and completed a movement disorders fellowship at the University Of Maryland School Of Medicine, receiving additional training in the management of Parkinson’s disease and tremor disorders there. He also completed an internal medicine internship and neurology residency at the University of Maryland Medical Systems and is a member of the American Academy of Neurology and the Movement Disorders Society.

  • John Scagnelli, MD

    Principal Investigator
    John Scagnelli, MD, specializes in Multiple Sclerosis and Adult Neurology. Dr. Scagnelli received his BS in Human Development from Cornell University and earned his MD from the University of Miami, Miller School of Medicine. He completed a National Multiple Sclerosis Society Fellowship to study the clinical care and research of patients with multiple sclerosis and related disorders at the University of Virginia, as well as a Neurology Residency at the University of Rochester, Strong Memorial Hospital. He is a member of the National MS Society and the American Academy of Neurology.

Learn More About Participating in a Clinical Trial

Liver Illustration with blog title, All About Liver Disease - Terminology, Early Detection, Symptoms and and Long Term Risk

All About Liver Disease

Liver disease is a growing concern across the globe, especially in the United States, where the prevalence of conditions like Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis … Read more

What is Informed Consent

What is Informed Consent?

Joining a clinical trial is an important decision. Most participants come to the clinic with questions about clinical trials and what joining one could mean. This is why every study … Read more

Clinical Trial Phases What Happens in Phase 1, 2, 3 and 4

Clinical Trial Phases: What Happens in Phase 1, 2, 3 and 4?

Clinical trials are research studies of medications, vaccines, medical devices, procedures, diagnostics (tests), and other health-related products. These studies involve participants (also known as patients, volunteers, or subjects) to determine … Read more

Maryann - research study participant testimonial

Participant Story: Maryann, a Research Study Participant at Velocity

What led you to participate in a research study? I saw a roadside poster near the university in my neighborhood [for a vaccine study] and called Velocity. My first experience … Read more

Complete the form to start your clinical trial journey in Raleigh

Why join a clinical trial?

  • Help advance medicine
  • Learn about potential new medicines in development
  • Get study-related medical exams at no cost
  • Receive compensation for participating (available amounts may differ for each study)

After you submit your info, a Velocity staff member will review your info. They will contact you to talk about the study, or others that may be right for you.

Health insurance is generally not needed to join a clinical trial.

Remember, there is never an obligation to join — we're here to help you make the best decision.

Submit your info

Sponsors and CROs

From the leading pharma companies, to the most pioneering biotech startups, Velocity supports those who are exploring new frontiers in human health. Whether you’re ready to conduct a single-site study or a complex, high-volume clinical trial, trust Velocity.

clinical research team

It all starts with people like you.

Without clinical trial participants, it would not be possible to create new medicines, treatments, and cures.